Cargando…
Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)
INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904165/ https://www.ncbi.nlm.nih.gov/pubmed/31875133 http://dx.doi.org/10.1136/bmjdrc-2019-000809 |
_version_ | 1783477963603312640 |
---|---|
author | Fokkert, Marion van Dijk, Peter Edens, Mireille Barents, Eglantine Mollema, Jeanine Slingerland, Robbert Gans, Reinold Bilo, Henk |
author_facet | Fokkert, Marion van Dijk, Peter Edens, Mireille Barents, Eglantine Mollema, Jeanine Slingerland, Robbert Gans, Reinold Bilo, Henk |
author_sort | Fokkert, Marion |
collection | PubMed |
description | INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Survey(v2) (SF-12(v2)) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months. RESULTS: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of −4 (95% CI −6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: −9 (95% CI −12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12(v2) mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively. CONCLUSIONS: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control. |
format | Online Article Text |
id | pubmed-6904165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-69041652019-12-24 Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) Fokkert, Marion van Dijk, Peter Edens, Mireille Barents, Eglantine Mollema, Jeanine Slingerland, Robbert Gans, Reinold Bilo, Henk BMJ Open Diabetes Res Care Emerging Technologies, Pharmacology and Therapeutics INTRODUCTION: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. METHODS: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Survey(v2) (SF-12(v2)) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months. RESULTS: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of −4 (95% CI −6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: −9 (95% CI −12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12(v2) mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively. CONCLUSIONS: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control. BMJ Publishing Group 2019-12-09 /pmc/articles/PMC6904165/ /pubmed/31875133 http://dx.doi.org/10.1136/bmjdrc-2019-000809 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Emerging Technologies, Pharmacology and Therapeutics Fokkert, Marion van Dijk, Peter Edens, Mireille Barents, Eglantine Mollema, Jeanine Slingerland, Robbert Gans, Reinold Bilo, Henk Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title | Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title_full | Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title_fullStr | Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title_full_unstemmed | Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title_short | Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4) |
title_sort | improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (flare-nl4) |
topic | Emerging Technologies, Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904165/ https://www.ncbi.nlm.nih.gov/pubmed/31875133 http://dx.doi.org/10.1136/bmjdrc-2019-000809 |
work_keys_str_mv | AT fokkertmarion improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT vandijkpeter improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT edensmireille improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT barentseglantine improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT mollemajeanine improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT slingerlandrobbert improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT gansreinold improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 AT bilohenk improvedwellbeinganddecreaseddiseaseburdenafter1yearuseofflashglucosemonitoringflarenl4 |